万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址（协办单位微信公众号信息）：
https://www.keaipublishing.com/en/journals/extracorporeal-life-support/
4、投稿网址：
https://www.editorialmanager.com/ecls/default2.aspx
5、官网邮箱：ecls.editorialoffice@gmail.com
6、出刊日期：官方暂未公布刊期信息。
7、协办单位微信公众号：体外生命支持分会ChELSA
8、官网信息：2026年12月31日前提交的稿件免除APC费用。
2026年6月17日星期三
邀稿启事 |《Extracorporeal Life Support》创刊号诚征佳作
【协办单位微信公众号信息】
体外生命支持分会ChELSA2026年2月27日
我们诚挚地邀请您，向《Extracorporeal Life Support》（ECLS）期刊投稿。本刊将于2026年首期正式出版，现面向全球学者、临床专家及科研工作者公开征集优秀稿件。
《Extracorporeal Life Support》（ECLS）是由科爱（KeAi Publishing）出版，融通医健期刊出版（北京）有限公司主办，并由中国心胸血管麻醉学会体外生命支持分会协办的高水平、国际化同行评议、开放获取期刊。ECLS期刊的创立旨在发表严谨、具有临床相关性且方法学可靠的研究。
在此，我们热情邀请您，将您在本领域的原创性研究、综述、共识、病例报道、评论或前瞻性观点等文章投稿至ECLS期刊。
ECLS接收的文章领域包括但不限于：
心肺与呼吸支持：体外膜肺氧合、体外循环、体外二氧化碳清除、临时机械循环支持、永久机械循环支持、心室辅助装置以及全人工心脏。
肾脏与肝脏支持：肾脏替代治疗、血液灌流、分子吸附再循环系统，生物人工或混合型肝支持系统。
神经支持与神经接口：多模态神经监测、脑灌注策略、体外神经保护方案，以及与生命支持和康复相关的脑机接口。
体外血液与免疫调控：成分分离技术、血浆置换、血液吸附、体外光化学疗法，以及靶向体外免疫治疗。
移植与器官替代：离体器官灌注与、围移植/移植后体外生命支持、生物工程/人工器官以及再生医学。
一体化与多器官平台：联合器官支持系统以及闭环监测与控制平台。
工程、数据科学与创新：器械设计、生物材料与生物相容性、传感器、人工智能与计算建模，以及转化研究。
伦理、政策与教育：临床指南、患者血液管理、医学伦理、培训与模拟以及与生命支持技术相关的卫生政策。
投稿事宜：
- 期刊网站：https://www.keaipublishing.com/en/journals/extracorporeal-life-support/
- 投稿系统：稿件请通过Elsevier Editorial System提交https://www.editorialmanager.com/ecls/default2.aspx
- 更多信息：请访问官网或联系编辑部。
联系方式：bozhiyuan@fuwai.com、ganjiaqi@fuwai.com
期待您的杰出贡献！
《Extracorporeal Life Support》编辑部 谨启
Guide for Authors
【官网信息】
About the journal
Journal announcements
Extracorporeal Life Support (ECLS) is an international, peer-reviewed, open-access journal published by Elsevier, managed by Rongtong Healthcare Journal Publishing (Beijing) Co., Ltd., and supported by ChELSA (the Extracorporeal Life Support Branch, Chinese Society of Cardiothoracic and Vascular Anesthesiology). Dedicated to the rapidly evolving interdisciplinary field of extracorporeal life and organ support, ECLS aims to provide a high-level platform integrating basic medicine, engineering innovation, and clinical translation, with a focus on publishing methodologically rigorous, clinically relevant, and impactful research.
Aims and scope
Extracorporeal Life Support (ECLS) is an international, peer-reviewed, open-access journal dedicated to advancing the science, engineering, and clinical practice of extracorporeal and organ-support therapies. The journal serves a multidisciplinary community of clinicians, scientists, engineers, ethicists, and allied health professionals across critical care, surgery, cardiology, pulmonology, nephrology, neurology, transplantation medicine, and biomedical engineering.
Aims
ECLS aims to publish rigorous, clinically relevant, and methodologically sound research that advances the science, engineering, ethics, and implementation of extracorporeal and organ‑support systems. The mission is to connect disciplines, standardize evidence, and promote equitable access to life‑support technologies worldwide.
Scope
The scope encompasses, but is not limited to:
Cardiopulmonary & Respiratory Support: extracorporeal membrane oxygenation (ECMO; VA/VV), cardiopulmonary bypass (CPB), extracorporeal carbon dioxide removal (ECCO₂R), temporary mechanical circulatory support, permanent mechnical circulatory support， ventricular assist devices (VADs), and total artificial hearts.
Renal & Hepatic Support: renal replacement therapies, hemoperfusion, molecular adsorbent recirculating system (MARS), and bioartificial or hybrid liver support.
Neurological Support & Interfaces: multimodal neuromonitoring, cerebral perfusion strategies, extracorporeal neuroprotective approaches, and brain–computer interfaces (BCIs) relevant to life support and rehabilitation.
Extracorporeal Blood & Immune Modulation: apheresis, plasma exchange, hemoadsorption, extracorporeal photopheresis, and targe ted extracorporeal immunotherapies.
Transplantation & Organ Replacement: ex‑vivo organ perfusion and machine preservation, peri‑/post‑transplant ECLS, bioengineered/artificial organs, and regenerative interfaces.
Integrated & Multi‑Organ Platforms: combined organ‑support systems and closed‑loop monitoring and control.
Engineering, Data Science & Innovation: device design, biomaterials and biocompatibility, sensors and miniaturization, artificial intelligence and computational modeling, and translational research bridging laboratory discoveries with clinical application.
Systems, Ethics, Policy & Education: clinical guidelines, patient blood management, medical ethics (indications, futility, equity, consent), training and simulation, implementation science, and health policy related to life‑support technologies.
Article types
ECLS publishes the following article types (word counts exclude abstract, references, tables, and figures unless noted):
Article type
Requirements
Original Article
≤ 7,000 words; structured abstract ≤ 350 words; up to 6 tables/figures combined; trial registration for clinical studies; STROBE/CONSORT/PRISMA/ARRIVE/CARE checklists as applicable.
Short Communication
≤ 2,000 words; ≤ 2 tables/figures; rapid communications of novel findings or devices.
Review Article
≤ 9,000 words; includes narrative reviews and comprehensive overviews of established topics.
Advances / Updates / State-of-the-Art Review
≤ 4,000 words; focused synthesis of new developments, trends, or translational advances in ECLS and organ support.
Systematic Review/Meta‑analysis
≤ 6,000 words; PRISMA checklist and flow diagram; registered protocol recommended.
Consensus/Guideline
No strict limit; follow AGREE II where applicable; include evidence- grading methodology (e.g., GRADE).
Case Report/Series
≤ 2,500 words; CARE checklist; must provide mechanistic or translational insight.
Perspective / Policy / Ethics
≤ 3,000 words; grounded in evidence and policy frameworks.
Trial Protocol / Registered Report
≤ 4,000 words; registration ID required; SPIRIT or registered‑report format.
Editorial
≤ 1,500 words; by invitation or linked to accepted content.
Commentary
≤ 1,500 words; expert opinion, contextual analysis, or response to published articles.
Letter to the Editor
≤ 1,000 words; concise commentary or discussion on recently published articles or emerging topics.
Peer review
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will be taken by our editors. This decision is final.
Our editors are not involved in making decisions about papers which:
they have written themselves.
have been written by family members or colleagues.
relate to products or services in which they have an interest.
Any such submissions will be subject to the journal's usual procedures and peer review will be handled independently of the editor involved and their research group.
All manuscripts are reviewed by the editorial office. Any papers which fail to meet the basic standards of the journal will be desk-rejected for reasons like out of scope, ethical conflicts, high similarities, lack of originality, flaws in research design or methods, etc. The editorial office will reassign selected papers to the Editor-in-chief.
The Editor-in-chief will invite multiple reviewers to review the paper or assign an editorial board member to invite reviewers to review this paper.
After at least two reviewers give their reviews and comments, the Editor-in-chief (or the assigned Editor) provides feedback to the authors, based on reviewer comments and his own review comments.
When the author submits the revised manuscript, the assigned editor and Editor-in-chief will collaborate to make a final decision.
For submissions from the Editor-in-Chief, Associate Editors, Guest Editor(s), other journal Board members, and authors who have conflicts of interest with them, we ensure that the paper is handled confidentially by a different team member.
For submissions to Special Issues; if there are conflicts of interest between the Guest Editor(s) and authors, the submissions will be handled by another Editor from the Editorial Board who will manage the peer review process and make the decision whether to accept or reject the paper after peer review.
Read more about peer review.
KeAi Guide for authors: Open Access
This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative Commons user licenses.
Creative Commons Attribution (CC BY)
Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); includes a link to the license; indicates if changes were made; and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Allows users to: distribute and copy the article; and include in a collective work (such as an anthology). These uses are permitted only for non-commercial purposes, and provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); provides a link to the license; and does not alter or modify the article.
If you need to comply with your funding body policy you can apply for a CC BY license after your manuscript is accepted for publication.
Article Publishing Charge (APC)
As an open access journal with no subscription charges, a fee (Article Publishing Charge, APC) is payable by the authors, or their institution or funders, to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
The open access publication fee for this journal is USD 1000, plus taxes. All APCs for articles submitted to the journal before the 31-December-2026 will be fully waived.
......
更多详见：
https://www.keaipublishing.com/en/journals/extracorporeal-life-support/guide-for-authors/
